User-centered design and clinical testing of an mhealth intervention to reduce alcohol-related harm
Active Project Grant Awarded Last action
- Award ID
- R44AA031393
- Recipient
-
Hart3S - A Social Purpose Corporation UEI JZL1MCCZ3UQ5
- Awarding agency
-
National Institute on Alcohol Abuse and Alcoholism
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,037,823
Award facts
- Assistance listing
- 93.273 Alcohol Research Programs
- Completion date 62% complete
- Place of performance
- Spokane, WA 99201, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alcohol-related deaths have increased by 29% in recent years. IT is this ever-growing global burden of alcohol- related harm that has propelled our team to conduct over 15 years of research to develop and scientifically test a highly flexible, patient-driven, low-barrier, in-person treatment known as harm and risk-reduction treatment for alcohol (HART-a). HART-a meets people where they are at to help them create goals to reduce alcohol-related harm and improve health-related quality of life, even if they are not ready, willing or able to stop drinking. Findings from our NIH-funded randomized clinical trials have shown the efficacy of low-barrier, in-person HART-a in reducing heavy alcohol use and alcohol-related harm and in improving health-related quality of life, even in a population that is socially marginalized and severely impacted by alcohol use disorder (AUD). However, the vast majority of people with AUD-approximately 85% in 2023-do not seek in-person treatment. Common barriers include the time, travel, and financial burden of in-person treatment services; their lack of patient-centeredness; and the stigma associated with treatment attendance. At the same time, recent years have seen a growing acceptance of and comfort with mobile health (MHEALTH) technologies. To leverage MHEALTH technology to reduce the aforementioned barriers to care, we collaborated with people with AUD and the providers who serve them to codevelop a mobile health version of HART-a (MHART-a). In our successfully completed sttr phase 1 project, our initial human-centered design and testing of the MHART-a prototype indicated strong laboratory-based usability (N=11) as well as strong field tests of feasibility and acceptability (N=31) among people with AUD. We are thus proposing a follow-up sttr phase 2 project, in which we will refine and optimize the MHART-a platform and conduct final usability and feasibility testing (N=30) aimed towards maximizing its scalability and commercialization potential. Then, we will rigorously test its efficacy in a 2-month randomized clinical trial (N=215). We hypothesize that participants receiving MHART-a will show significant improvements on alcohol outcomes and health-related quality of life compared to a no-treatment control group. If successful, our combined sttr phase 1 and phase 2 projects will have built a strong evidence base to propel MHART-a towards widespread adoption and commercial viability. This NIH-funded work will support the broad dissemination of an accessible and efficacious alcohol intervention to the tens of millions of people with AUD who are not currently receiving help.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $1,037,823 |
Quick answers
Who received award R44AA031393?
R44AA031393 was awarded to Hart3S - A Social Purpose Corporation by National Institute on Alcohol Abuse and Alcoholism (National Institutes of Health) on March 1, 2024.
How much is award R44AA031393 worth?
$1,037,823 has been obligated on R44AA031393.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award